If you are a foreign grant administrator, don’t miss three new G11 Sample Grant Applications and a refresher on the associated NIAID funding opportunity Global Infectious Disease Research Administration Development Award for Low- and Middle-Income Country Institutions (G11, Clinical Trial Not Allowed).

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research to understand, treat, and prevent infectious and allergic diseases.

Sep 12, 2023 · NIH published the PAR-23-300, Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed) notice of funding opportunity (NOFO) on September 12, 2023. September 14, 2023. All questions and answers below after the first one are new.

Sep 12, 2023 · National Institute of Allergy and Infectious Diseases (NIAID) G11 Extramural Associate Research Development Award (EARDA) March 31, 2025 - This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.

The National Institute of Allergy and Infectious Diseases (NIAID, / ˈ n aɪ. æ d /) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS).

Dec 3, 2024 · The goal is to improve oversight of NIAID grant awards and compliance with NIH funding policies and Federal research funding requirements for NIAID-supported foreign institutions in LMICs. Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations). NIH Grants Information [email protected].

The ultimate goal is to improve oversight of NIAID grant awards and compliance with NIH funding policies and Federal research funding requirements for NIAID-supported foreign institutions in low to middle-income countries.

Aug 27, 2020 · The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced that it has awarded 11 grants with a total first-year value of approximately $17 million to establish the Centers for Research in Emerging Infectious Diseases (CREID).

IMPAACT 2019: Phase 1/11 open-label, multicenter, multiple-dose study of Triumeq@ and Triumeq in children living with HIV Triumeq contains dolutegravir, abacavir, and lamivudine in a dispersible tablet Safe, well-tolerated and effective at controlling HIV when taken daily 23

Aug 4, 2011 · NIAID requires accurate, timely information about the status of hundreds of ongoing and planned studies. New insights into the biology of HIV disease are rapidly emerging, resulting in novel hypotheses and agents to test.